戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              MMPI-2 results were of questionable validity because of
2 nnesota Multiphasic Personality Inventory 2 (MMPI-2) was administered to 19 LNP subjects self-describ
3 udes Test-26, Eating Disorder Inventory, and MMPI-II, was similar for both patient groups.
4 show variability in rats and mice to LPS and MMPIs, which most likely is based on genetic make-up.
5 he first report to show a positive effect by MMPIs on chronic relapsing EAE, its central nervous syst
6 Is, we discovered a new class of fluorinated MMPIs with a triazole-substituted hydroxamate substructu
7 umulated data, it is recommended that future MMPI trials focus on: (1) patients with early stage canc
8              Investigations with hydroxamate MMPIs, including those designed for deep pocket MMPs, al
9 ial scarring were significantly decreased in MMPI-treated mice with chronic relapsing EAE, as was cen
10 r MMP inducer; Prinomastat [a MMP inhibitor (MMPI)] significantly decreased cyclic strain-induced pro
11         Matrix metalloproteinase inhibitors (MMPIs) reduce blood-brain barrier (BBB) disruption and p
12 olidine matrix metalloproteinase inhibitors (MMPIs) were designed, synthesized, and evaluated.
13 e-based matrix metalloproteinase inhibitors (MMPIs).
14 cked by matrix metalloproteinase inhibitors (MMPIs).
15             However, no such MMP inhibitors (MMPIs) are available to date as drug candidates despite
16 alized by using radiolabeled MMP inhibitors (MMPIs) as positron emission tomography (PET) imaging age
17 tablished using radiolabeled MMP inhibitors (MMPIs) as tracers for the detection of activated MMPs by
18 l evolution of the synthetic MMP inhibitors (MMPIs) is also examined, with the discussion encompassin
19 IMP-2, and several synthetic MMP inhibitors (MMPIs) on the shedding of both tumor necrosis factor alp
20                Consequently, MMP inhibitors (MMPIs) radiolabeled with positron emitting nuclides (e.g
21 ell tolerated, orally active MMP inhibitors (MMPIs) which demonstrated efficacy in mouse cancer model
22 f new potent mercaptosulfide MMP inhibitors (MMPIs) with Leu or homophenylalanine (Homophe) side chai
23 Minnesota Multiphasic Personality Inventory (MMPI-2) in 1986.
24 Minnesota Multiphasic Personality Inventory (MMPI-2) Type A Scale.
25 nd unlabeled derivatives of the nonselective MMPIs, we discovered a new class of fluorinated MMPIs wi
26                                  These novel MMPIs are characterized by an increased hydrophilicity c
27 ciated with determining clinical efficacy of MMPIs and other novel therapeutic agents.
28                In retrospect, the failure of MMPIs to alter disease progression in metastatic cancer
29 damage would be more useful for screening of MMPIs.
30 mportant clues that could guide selection of MMPIs in treatment of neurological diseases.
31 inued their ongoing Phase III drug trials of MMPIs in advanced cancer.
32 ents with early stage cancer; (2) the use of MMPIs along with chemotherapy; (3) the measurement of MM
33      Exhibiting unique properties over other MMPIs (e.g., hydroxamates), these newly reported compoun
34                              Pharmacological MMPIs should be considered in the pursuit of therapeutic
35         In this study, we show that a potent MMPI was clinically effective in an animal model for MS,
36                Results reveal legume protein MMPIs as novel metalloproteinase inhibitors with possibl
37 Descriptions of individual patients resemble MMPI profiles, based on the degree of match between the
38 s in a delayed opening of the BBB, to screen MMPIs to identify therapeutic agents.
39 blance among these MMPs, designing selective MMPIs is quite challenging.
40 em promising targets for designing selective MMPIs.
41 urtain raiser for the designing of selective MMPIs as drug candidates in the future.
42    Initially, we tested three broad-spectrum MMPIs in the rat, BB-1101, BB-94, and BB-2293, and a MMP
43 ethylprednisolone and several broad-spectrum MMPIs, including BB-1101, was ineffective in the C57/BL6
44 he initially discovered triazole-substituted MMPIs, an additional CH2-group between the backbone of t
45                         Triazole-substituted MMPIs, discovered by our group, are highly potent inhibi
46 -dependent manner by the following synthetic MMPIs: batimastat and marimastat (BB-94 and BB-2516, res
47 or the pharmacological activity of synthetic MMPIs.
48                                The synthetic MMPIs and TIMP-2, but not TIMP-1, also caused a dose-dep
49 equired with low molecular weight, synthetic MMPIs but at concentrations greater than those required
50                     This study suggests that MMPIs, protein sequence analyses, and molecular modeling
51                                          The MMPI-2 showed a high score on the "lie" validity scale f
52                                          The MMPI-2 Type A Scale predicts CHD incidence.
53                                          The MMPI/MMPI-2 remains the most popular instrument for both
54  free of diagnosed CHD in 1986 completed the MMPI-2 Type A Scale.
55 egorized according to their responses to the MMPI-2 Anger Content Scale, which measures the degree to
56 g patients who are more likely to respond to MMPI therapy; and (4) identification of biomarkers that
57 bstituted hydroxamates, the inverse triazole MMPIs are excellent inhibitors with promising in vivo pr
58 cterial meningitis respond to treatment with MMPIs.
59 pared the response to LPS and treatment with MMPIs.